Achieved $39.1 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues and $63.3 million in total revenues in the first quarter of 2023 --
-- Raising 2023 AYVAKIT net product revenue guidance to $135 million to $145 million for advanced SM and GIST, excluding additional revenue associated with anticipated U.S. FDA approval for indolent SM --
-- FDA target action date for AYVAKIT supplemental new drug application for indolent SM is May 22, 2023 --
https://www.biospace.com/article/releases/blueprint-medicines-reports-first-quarter-2023-results/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.